Aurobindo Accelerates Biosimilars Efforts With Second Filing
As Company Makes Seven Drug Launches in Q3 FY22
Aurobindo has filed for its second oncology biosimilar with the EMA in January 2022, as the company remains on track to develop its biosimilars portfolio in both oncology and immunology segments. The company has also launched seven products, including four injectables, in its financial third quarter ended 31 December 2021.
